AlloVir Taps Merck’s Atillasoy as Chief Regulatory & Safety Officer

AlloVir (NASDAQ: [[ticker:ALVR]]) has appointed Ercem Atillasoy to serve as its chief regulatory and safety officer, a new position. He joins the Cambridge, MA-based cell therapy developer after a nearly 20-year career at Merck (NYSE: [[ticker:MRK]]). He most recently worked at Merck Research Laboratories, where he was vice president and therapeutic area head of vaccines and infectious disease.

AlloVir is developing allogeneic cell therapies to prevent and treat viral infections in patients undergoing transplant procedures. In July, the biotech’s IPO raised $276.3 million to fund Phase 3 tests of its lead therapeutic candidates.

Author: Frank Vinluan

Xconomy Editor Frank Vinluan is a business journalist with experience covering technology and life sciences. Based in Raleigh, he was a staff writer at the Triangle Business Journal covering technology, biotechnology and energy before joining MedCityNews.com as North Carolina bureau chief. Prior to moving to North Carolina’s Research Triangle in 2007 he held business reporting positions at The Des Moines Register and The Seattle Times.